Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Marinus Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRNS's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MRNS underperformed the US Pharmaceuticals industry which returned 7.2% over the past year.
Return vs Market: MRNS underperformed the US Market which returned 6.9% over the past year.
Price Volatility Vs. Market
How volatile is Marinus Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StAre Institutions Heavily Invested In Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Shares?
1 month ago | Simply Wall StMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Insiders Increased Their Holdings
2 months ago | Simply Wall StIs Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Deliver On Growth Plans?
Is Marinus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MRNS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MRNS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MRNS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: MRNS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MRNS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MRNS is overvalued based on its PB Ratio (3.7x) compared to the US Pharmaceuticals industry average (3.3x).
How is Marinus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRNS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MRNS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MRNS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if MRNS's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if MRNS's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MRNS's Return on Equity is forecast to be high in 3 years time
How has Marinus Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRNS is currently unprofitable.
Growing Profit Margin: MRNS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MRNS is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.
Accelerating Growth: Unable to compare MRNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRNS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).
Return on Equity
High ROE: MRNS has a negative Return on Equity (-84.57%), as it is currently unprofitable.
How is Marinus Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MRNS's short term assets ($80.0M) exceed its short term liabilities ($10.3M).
Long Term Liabilities: MRNS's short term assets ($80.0M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: MRNS is debt free.
Reducing Debt: MRNS has no debt compared to 5 years ago when its debt to equity ratio was 20.2%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRNS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MRNS has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 23.9% each year.
What is Marinus Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MRNS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MRNS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRNS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRNS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRNS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Braunstein (57yo)
Dr. Scott Braunstein, M.D., serves as Director at Protara Therapeutics, Inc. (formerly known as ArTara Therapeutics, Inc.). since June 2018. He served as Chairman of the Board at ArTara Therapeutics, Inc) ...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD2.25M) is above average for companies of similar size in the US market ($USD1.34M).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||0.92yr||US$2.25m||0.082% $184.0k|
|VP, CFO||6.67yrs||US$1.25m||0.015% $32.6k|
|Chief Medical Officer||0.75yr||US$734.30k||no data|
|Executive Director of Investor & Strategic Relations||no data||no data||no data|
|VP, General Counsel & Secretary||0.083yr||no data||no data|
|Vice President of Investor Relations & Corporate Communication||0.33yr||no data||no data|
|Vice President of Corporate||no data||no data||no data|
|Vice President Regulatory Affairs||no data||no data||no data|
|Head of Scientific Affairs||no data||no data||no data|
Experienced Management: MRNS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
|CEO, President & Director||0.92yr||US$2.25m||0.082% $184.0k|
|Independent Chairman of the Board||0.92yr||US$174.94k||0.041% $92.6k|
|Independent Director||3.42yrs||US$162.70k||0.0074% $16.6k|
|Independent Director||11.58yrs||US$180.47k||0.041% $92.6k|
|Independent Director||0.58yr||US$154.32k||no data|
|Independent Director||3.83yrs||US$161.20k||0.0091% $20.4k|
|Independent Director||6.67yrs||US$158.96k||0.026% $58.5k|
Experienced Board: MRNS's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 132.5%.
Marinus Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Marinus Pharmaceuticals, Inc.
- Ticker: MRNS
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$224.838m
- Shares outstanding: 122.19m
- Website: https://www.marinuspharma.com
Number of Employees
- Marinus Pharmaceuticals, Inc.
- 5 Radnor Corporate Center
- Suite 500
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MRNS||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Aug 2014|
|0MV||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2014|
|MRNS *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Aug 2014|
|0JYL||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Aug 2014|
Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/15 23:59|
|End of Day Share Price||2020/07/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.